Extended stability data for the reference Herceptin have been published, supporting advanced preparation and dose banding. Given stability data for SB3 are limited, a new study sought to assess the extended physiochemical stability and bioactivity of the biosimilar and to evaluate the advanced preparation of the reconstituted and diluted product.
Samsung Bioepis’ SB3, approved under the name Ontruzant in the United States and European Union, is a biosimilar trastuzumab referencing Herceptin.
Like that of its reference, SB3’s product information highlights the need for aseptic conditions during handling, as the product is for a single use and does not contain a preservative. Under aseptic conditions, SB3, like Herceptin, is physically and chemically stable for 48 hours after reconstitution with sterile water and stored at 2°C to 8°C. Diluted SB3 is also physically and chemically stable for 24 hours up to 30°C when stored in in polyvinylchloride, polyethylene, or polypropylene bags containing 0.9% normal saline.
Extended stability data for the reference Herceptin have been published, supporting advanced preparation and dose banding. Given stability data for SB3 are limited, a new study, published in Advances in Therapy, sought to assess the extended physiochemical stability and bioactivity of the biosimilar and to evaluate the advanced preparation of the reconstituted and diluted product.
Under controlled, aseptic conditions, researchers assessed the stability of reconstituted and diluted SB3 according to UK National Health Service guidance, then stored the reconstituted product at 25°C  (± 2°C) with 60% (±5%) relative humidity for 3 days. Next, diluted SB3 was stored in an infusion bags in the absence of light at 25°C  (±2°C) with 60% (±5%) relative humidity for 28 days, and 5°C (±3°C) for 28 days, respectively.
Then, physiochemical stability, biological activity, and properties that could impact safety—such as subvisible particulates or submicronic aggregation) were determined.
The investigators found no signs of physiochemical instability or any changes in biological activity for either reconstituted or diluted biosimilar up to day 28. No major change was observed in the proportion of molecular weight variants or relative percentages of acidic, main, and basic charge isoforms of the protein. No increases in particulate or aggregates that could impact safety were noted.
Furthermore, the study included an evaluation of samples at 1 time point beyond the proposed storage period of 28 days; at 33 days of additional storage, the proportion of high molecular weight impurity was not changed.
These findings, write the researchers, further support the physicochemical stability and maintained biological activity of reconstituted SB3 under proper storage conditions, and may help reduce the need to discard unused SB3 doses and to allow for advanced preparation without impacting the quality or biological activity of the product.
Reference
Yun J, Kim J, Chung J, Hwang SJ, Park SJ. Extended stability of reconstituted and diluted SB3 (trastuzumab biosimilar) assessed by physiochemical and biological properties [published online May 17, 2019]. Adv Ther. doi: 10.1007/s12325-019-00973-y.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.